Roivant Sciences Ltd

ROIV

Healthcare|Biotechnology|UK

$35.98

-0.86 (-2.34%)

Tangible Book

$6.29

About

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Stock Price

+211.0%(1Y)

Pipeline Summary

2 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Completed: 2

BioScore

5/10

Watchlist

Ownership

Recent Insider Trades

QVT Financial LPSELL

2026-06-301,438,163 shares @ $34.32

MANCHESTER KEITH SSELL

2026-06-301,638,163 shares @ $34.46

Gold Daniel AllenSELL

2026-06-301,438,163 shares @ $34.32

Fitzgerald MeghanSELL

2026-06-3010,000 shares @ $34.9

Epperly Melissa B,SELL

2026-06-2917,750 shares @ $34.38

Data last updated: Jul 12, 2026, 07:28 PM